Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.
NCT06311942
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
300
Enrollment
OTHER
Sponsor class
Conditions
HCC
Interventions
DRUG:
HAIC plus PD-1 inhibitors plus lenvatinib
DRUG:
PD-1 inhibitors plus lenvatinib
Sponsor
Chen Xiaoping